- Home
- MLR vs IMNM Comparison
MLR vs IMNM Comparison
Compare MLR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLR
- IMNM
- Stock Information
- Founded
- MLR 1990
- IMNM 2006
- Country
- MLR United States
- IMNM United States
- Employees
- MLR N/A
- IMNM N/A
- Industry
- MLR Construction/Ag Equipment/Trucks
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- MLR Consumer Discretionary
- IMNM Health Care
- Exchange
- MLR Nasdaq
- IMNM Nasdaq
- Market Cap
- MLR 769.3M
- IMNM 747.7M
- IPO Year
- MLR 1994
- IMNM 2020
- Fundamental
- Price
- MLR $67.78
- IMNM $11.04
- Analyst Decision
- MLR Strong Buy
- IMNM Strong Buy
- Analyst Count
- MLR 1
- IMNM 5
- Target Price
- MLR $82.00
- IMNM $28.60
- AVG Volume (30 Days)
- MLR 85.1K
- IMNM 820.2K
- Earning Date
- MLR 11-12-2024
- IMNM 11-13-2024
- Dividend Yield
- MLR 1.12%
- IMNM N/A
- EPS Growth
- MLR 35.81
- IMNM N/A
- EPS
- MLR 6.02
- IMNM N/A
- Revenue
- MLR $1,331,839,000.00
- IMNM $10,129,000.00
- Revenue This Year
- MLR $16.10
- IMNM N/A
- Revenue Next Year
- MLR $6.72
- IMNM N/A
- P/E Ratio
- MLR $11.26
- IMNM N/A
- Revenue Growth
- MLR 22.98
- IMNM N/A
- 52 Week Low
- MLR $38.33
- IMNM $8.05
- 52 Week High
- MLR $78.25
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- MLR 38.82
- IMNM 43.70
- Support Level
- MLR $71.24
- IMNM $12.99
- Resistance Level
- MLR $72.80
- IMNM $15.13
- Average True Range (ATR)
- MLR 1.99
- IMNM 0.93
- MACD
- MLR -0.76
- IMNM -0.16
- Stochastic Oscillator
- MLR 4.72
- IMNM 3.79
About MLR Miller Industries Inc.
Miller Industries Inc is engaged in the manufacturing of vehicle towing and recovery equipment. The company produces wreckers, car carriers, and trailer bodies under the Century, Vulcan, Challenger, Holmes, Champion, Chevron, Eagle, Titan, Jige, and Boniface brands. The products are sold in North America, Canada, and Mexico through independent distributors.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.